IGC PHARMA, INC.

IGC ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Operating Activities
Net Income $-1.9M $-2.8M $-4.6M $-3.0M $-2.3M $-7.8M $-20.2M
Depreciation & Amortization $396.3K $728.7K $781.5K $712.3K $673.9K $996.4K $785.1K
Depreciation $712.3K $673.9K $996.4K $785.1K
Amortization
Stock-Based Compensation $250.6K $214.3K $833.1K $181.0K $824.8K $-23.3K
Net Cash from Operating Activities $-1.4M $-157.7K $-2.6M $-1.7M $564.8K $-5.0M $-2.6M
Investing Activities
Capital Expenditures $145.7K $122.2K $76.5K $8.5K $326.1K $5.5K $285.4K
Business Acquisitions $0 $-16.4K $-165.9K $0 $0 $-2.7M
Net Cash from Investing Activities $-241.4K $-183.4K $-518.1K $3.1K $-74.7K $4.7M $-44.7K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $707.6K $1.0M $2.9M $1.7M $27.7K $-625.8K $3.4M
Net Change in Cash $-952.7K $666.2K $-202.1K $-37.9K $501.5K $-1.0M $740.4K
Free Cash Flow $-1.5M $-279.9K $-2.7M $-1.8M $238.8K $-5.0M $-2.9M
← Newer Page 2 of 2 Older →